Speaker Profile
Biography
David A. Sinclair, A.O., Ph.D. is one of the worlds most influential scientists and a leading figure in the study of human longevity. A tenured Professor of Genetics at Harvard Medical School, he best known for his research on the role of sirtuins, NAD+ metabolism, and aging as information loss. In 2020, his lab reported successful use of reprogramming to safely reverse aging in mammals. Professor Sinclair served as Founding Director of the Glenn Center for Biology of Aging Research at Harvard and has published over 200 articles cited 100,000 times. He is inventor on more than 50 patents and has co-founded over a dozen successful companies including MetroBiotech and Life Biosciences. He is a New York Times bestselling author of Lifespan and the host of Lifespan. Among 36 awards, he was recognized as one of TIME Magazines 100 Most Influential People, Noble Genius Prize Officer of the Order of Australia (A.O.)
Talk
Age reversal in the clinic: How safe? How soon?
Dr. Sinclair will be presenting his latest research and clinical update on making safe age reversal possible
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, UCLA
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Luigi Ferrucci, NIH
• Sara Hägg, Karolinska Institutet
• Steve Horvath, UCLA
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, Trudiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Sherry Zhang, Buck Institute
• Nathan Price, THORNE
• Ranjan Sinha, digbi Health
Epigenetic Rejuvenation & Delivery for Clinical Translation
• Ryan (Yuancheng) Lu, Whitehead Institute/MIT
• David Sinclair, Harvard
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Medicine
Precision Aging & Longevity: Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
• Michael Gurven, UC Santa Barbara




